The share price of GENFLEET-B (ASX: 02595) has charted a classic inverted V-shape trajectory since March this year. Observers note that as early as February, the company announced its inclusion in several key indices, including the Hang Seng Composite Index, the Hang Seng Stock Connect Hong Kong Index, the Hang Seng Innovative Medicine Index, and the MSCI Global Small Cap Index. Its selection for the MSCI index less than six months after listing, particularly as an 18A company, garnered significant market attention. Consequently, following the official activation of its Stock Connect inclusion on March 9th, its share price embarked on a volatile upward climb, nearly doubling within two months to reach an intraday high of HK$52.90 on April 27th, setting a new record since its IPO.
However, after peaking, the stock price rapidly reversed course, closing down 2.75% that same day and initiating a prolonged downtrend. Over the next two months, the price continued to fall, dropping to a low of HK$27.68 by June 16th, effectively erasing nearly all gains made since March.
The Rollercoaster Journey in Detail
The share price surged from an intraday low of HK$23.22 on March 5th to the peak of HK$52.90 on April 27th, representing a maximum gain of 127.82% during that period. Beyond the Stock Connect inclusion, positive developments in its RAS-targeted therapy pipeline were a core driver of this two-month doubling. Chart analysis shows the price generally exhibited a volatile upward trend between March 5th and April 27th, though the catalysts for each surge phase differed.
The first significant price jump occurred over two trading days on March 9th and 10th, coinciding with the official Stock Connect inclusion. As pre-inclusion controlling funds exited, the stock benefited from substantial buying interest from southbound Stock Connect funds, attracted by its prior "grand slam" of index inclusions. This led to daily gains of 20.80% and 8.18% on those respective days. However, on March 10th, heavy selling pressure caused a sharp intraday pullback, forming a long upper shadow on the candlestick and sparking some panic, which contributed to a subsequent "seven consecutive down days" pattern.
Following this consolidation, the price found support and halted its decline. A bullish technical pattern emerged around the middle Bollinger Band on March 20th, preceding a sustained rally. A key driver during this second phase was positive news flow regarding RAS-targeted therapies. In April, Revolution Medicines announced that its investigational pan-RAS inhibitor, daraxonrasib (RMC-6236), successfully met all primary and secondary survival endpoints in a Phase III trial for previously treated advanced pancreatic cancer. On April 14th, GENFLEET-B's stock gapped up at the open, surging over 22% intraday before closing up 17.18%.
This reaction was linked to GENFLEET-B's own pipeline, which includes an oral molecular glue pan-RAS inhibitor, GFH276, positioning the company as a potential global leader in next-generation RAS therapies. GFH276 is the first such inhibitor in China and the third globally to enter clinical trials. The positive data from Revolution's trial provided substantive validation for the scientific feasibility of the pan-RAS molecular glue mechanism, representing a significant boost for GFH276, which is in the same therapeutic class.
Nevertheless, the persistently rising price eventually led to profit-taking. From a volume perspective, a clear divergence between price and volume became increasingly apparent during the rally from March 20th to April 14th. Daily trading volume trended downward even as the price rose, signaling waning bullish momentum and an impending reversal.
The subsequent decline in GENFLEET-B's share price also correlated with broader weakness in the Hong Kong healthcare sector.
Following the Sector's Ebb and Flow
Since last September, the Hong Kong innovative drug sector has shifted from a bull market to a pattern of volatile decline, with a particularly persistent downtrend emerging after mid-April this year. This directly pulled the Hang Seng Healthcare Index lower, which has fallen approximately 23.17% from April 16th to the present.
This sector-wide weakness stems from a confluence of factors including capital flows, market sentiment, and geopolitics. Regarding capital, strong performance in themes like AI computing power and semiconductors in the first half of the year attracted a significant portion of active market funds. In contrast, innovative drugs, being a long-cycle sector with infrequent catalysts, faced notable liquidity diversion in a market characterized by存量 funds competition.
Furthermore, increasingly tense global geopolitics have heightened uncertainty around the U.S. Federal Reserve's monetary policy. Recent market expectations for delayed rate cuts or even potential hikes have contributed to tighter global liquidity. For rate-sensitive assets like innovative drug stocks, this directly pressures valuation levels.
While industry fundamentals show strength—with total Business Development (BD) deal value for domestic innovative drugs surpassing $60 billion in a single quarter of 2026, accounting for nearly 70% of global pharmaceutical deal volume—the market reaction differs from last year's bull run, which was heavily driven by BD news. The current tepid secondary market response to robust industry BD activity indicates the sector is gradually moving away from pure event-driven trading and entering a phase of more nuanced, fundamentals-based pricing.
In short, investors are no longer solely evaluating companies based on the nominal total value of BD deals. Instead, they are incorporating factors like deal structure, timing of revenue realization, cash flow certainty, and profitability alignment across markets into a layered valuation approach. The marginal impact of event-driven positive news is waning, with the ability to deliver on fundamentals becoming the core consideration for valuation differentiation. This environment is challenging for companies like GENFLEET-B that are not yet profitable.
Examining the Company's Fundamentals
Fundamentally, GENFLEET-B's pipeline extends beyond its marketed KRAS G12C inhibitor, Fuzereisai. Its innovative pipeline covers various selective inhibitors (GFH375 for KRAS G12D), pan-RAS inhibitors (GFH276), and includes small molecule targeted drugs, non-degrading molecular glues, and novel antibody-drug conjugates with innovative mechanisms (GFS784 for panRAS). Several of these candidates are first-in-class or among the leading candidates in their respective domestic fields.
Notably, GFH375, an oral small molecule inhibitor targeting the KRAS G12D mutation and a core asset in its pipeline, held an investigator meeting for its pancreatic cancer Phase III trial as early as late February this year, being the first oral KRAS G12D inhibitor globally to enter Phase III. In early March, it was granted Breakthrough Therapy Designation by China's CDE, becoming the first KRAS G12D inhibitor in China to receive this recognition.
However, the company has not yet achieved profitability from product sales. According to its disclosed 2025 financial report, revenue was RMB 130 million, a year-on-year increase of 24.42%, but the net loss widened significantly by 164.82% to RMB 1.795 billion. Such fundamentals are clearly at odds with the current investment preferences within the Hong Kong innovative drug sector. This misalignment suggests that, in the absence of major catalysts, the company's share price is likely to experience relatively higher volatility.
Comments